Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aspyrian Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3051
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a clinical stage biotechnology company that develops first-in-class precision targeted cancer drugs for the treatment of solid tumors. The company harnesses the Photoimmunotherapy (PIT) platform to develop its products. Its lead pipeline product candidate, RM-1929, an antibody conjugate of cetuximab and IRDye 700DX, targeting epidermal growth factor receptors (EGFR), which find expression in various types of solid tumors, including cancers of the head and neck, colon, esophagus, lung, pancreas and others. This first-in-class treatment harnesses an antibody conjugate to accurately act against cancer cells by activating the conjugated dye with red light to draw quick anti-cancer responses. Aspyrian Therapeutics is headquartered in San Diego, California, the US.

Aspyrian Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Aspyrian Therapeutics Raises USD15 Million in Series B-1 Financing 10
Aspyrian Therapeutics Raises Additional USD15.2 Million in Series B Venture Financing 11
Aspyrian Therapeutics Raises USD40 Million in Series B Financing Round 12
Aspyrian Therapeutics Raises USD4.25 Million in Extended Series A Financing 13
Aspyrian Therapeutics Raises USD2 Million in Venture Financing 14
Licensing Agreements 15
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 15
Aspyrian Therapeutics Inc – Key Competitors 16
Aspyrian Therapeutics Inc – Key Employees 17
Aspyrian Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product News 19
04/27/2017: Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options 19
Clinical Trials 20
Jan 16, 2018: Aspyrian Therapeutics announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer 20
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aspyrian Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aspyrian Therapeutics Raises USD15 Million in Series B-1 Financing 10
Aspyrian Therapeutics Raises Additional USD15.2 Million in Series B Venture Financing 11
Aspyrian Therapeutics Raises USD40 Million in Series B Financing Round 12
Aspyrian Therapeutics Raises USD4.25 Million in Extended Series A Financing 13
Aspyrian Therapeutics Raises USD2 Million in Venture Financing 14
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 15
Aspyrian Therapeutics Inc, Key Competitors 16
Aspyrian Therapeutics Inc, Key Employees 17

List of Figures
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aspyrian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aspyrian Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Swelect Energy Systems Ltd (SWELECTES):企業の財務・戦略的SWOT分析
    Summary Swelect Energy Systems Ltd(SESL), is an energy company that manufactures and markets renewable energy products and iron and steel products. The company’s renewable energy products include solar pv modules, solar inverter, solar water pump and energy efficient lighting. SESL offers iron and s …
  • Kimco Realty Corporation (KIM):企業の財務・戦略的SWOT分析
    Kimco Realty Corporation (KIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Kepler Weber SA (KEPL3):企業の財務・戦略的SWOT分析
    Kepler Weber SA (KEPL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Energizer Holdings, Inc.:戦略・SWOT・企業財務分析
    Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Colefax Group Plc:企業の戦略・SWOT・財務情報
    Colefax Group Plc - Strategy, SWOT and Corporate Finance Report Summary Colefax Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • The Bank of East Asia, Limited:企業のM&A・事業提携・投資動向
    The Bank of East Asia, Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bank of East Asia, Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Seegene Inc (096530):企業の財務・戦略的SWOT分析
    Summary Seegene Inc (Seegene) is a diagnostic company that develops molecular diagnostic reagents. The company provides products such as seeplex, anyplex and magicplex among others. It develops ACP, DPO, READ, MuDT and TOCE technologies that enables to detect multiple pathogens in single reactions u …
  • Hague and London Oil PLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Hague and London Oil PLC (HALO), formerly Wessex Exploration plc, is an oil and gas exploration company that develops resource properties. The company acquires, explores, produces, and develops oil and gas resource properties across the UK. Its projects comprise assets in the Philippines, Gu …
  • The Walsh Group:企業の戦略的SWOT分析
    The Walsh Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • SMART Medical Systems Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Smart Medical Systems Ltd (Smart) is a medical device company that develops and manufactures gastroenterology and GI endoscopy devices. The company offers products such as inflation systems, platform, naviaid ABC, G-eye, naviaid AB, future naviaid products, controlled withdrawal, and others. …
  • The Hub Power Co Ltd (HUBC):企業の財務・戦略的SWOT分析
    The Hub Power Co Ltd (HUBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Weis Markets, Inc.:戦略・SWOT・企業財務分析
    Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Florida Keys Electric Cooperative Association, Inc.:企業の戦略的SWOT分析
    Florida Keys Electric Cooperative Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compe …
  • Rex Energy Corporation (REXX)-石油・ガス分野:企業M&A・提携分析
    Summary Rex Energy Corporation (Rex Energy) is an independent energy company. It carries out the acquisition, production, exploration and development of condensate, natural gas and natural gas liquids. It holds properties in Appalachian Basin. Rex Energy focuses on drilling and exploration activitie …
  • Cargill, Incorporated:企業のM&A・事業提携・投資動向
    Cargill, Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cargill, Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Pick N Pay Stores Limited:企業の戦略・SWOT・財務分析
    Pick N Pay Stores Limited - Strategy, SWOT and Corporate Finance Report Summary Pick N Pay Stores Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Mustek Limited (MST):企業の財務・戦略的SWOT分析
    Mustek Limited (MST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bourbon Corp:企業の戦略・SWOT・財務分析
    Bourbon Corp - Strategy, SWOT and Corporate Finance Report Summary Bourbon Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Octapharma AG:企業の戦略・SWOT・財務分析
    Octapharma AG - Strategy, SWOT and Corporate Finance Report Summary Octapharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Boeing Co (BA):企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆